Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin64.3%0.0pp64.3%+0.4pp63.9%+0.3pp63.6%+1.1pp62.5%+0.7pp
Operating margin10%-2.5pp12.6%-2.9pp15.5%+1.1pp14.3%+2.1pp12.3%+4.5pp
Net margin14.3%+0.9pp13.4%-3.0pp16.4%+1.1pp15.2%+2.2pp13.1%+4.5pp
Returns
Return on equity27.1%-1.3pp28.3%-10.5pp38.9%+1.5pp37.4%+3.9pp33.5%+10.5pp
Return on invested capital114.6%-52.8pp167.3%-92.1pp259.4%
Efficiency
Asset turnover1.3×-0.1×1.5×-0.1×1.6×
Liquidity
Current ratio4.6×-0.3×4.9×+0.7×4.1×+0.2×3.9×+0.2×3.7×+0.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.1×0.0×0.1×0.0×
Net debt / EBITDA-4.6×-0.9×-3.6×-0.6×-3×+0.2×-3.3×
Per Share
Book value per share$0.97+8.7%$0.90+9.8%$0.82+9.6%$0.74+12.0%$0.66+12.7%
Valuation
Market capitalization$254.07M-74.9%
Price / earnings13.6×-43.5×
Price / sales-6.8×
Price / book3.3×-13.6×
EV / EBITDA15×-44.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Niagen Bioscience, Inc. Common Stock's profit margins?
Niagen Bioscience, Inc. Common Stock (NAGE) runs a 64.3% gross margin and a 10.0% operating margin, with a 14.3% net margin.
Where do Niagen Bioscience, Inc. Common Stock's ratios come from?
Every ratio is computed from Niagen Bioscience, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.